Gastroesophageal Reflux Disease Clinical Trial
Official title:
Diagnostic Efficacy of Narrow Band Imaging (NBI) in Patients With Gastroesophageal Reflux Disease (GERD)
Gastroesophageal reflux disease (GERD) is a common disorder in Asia that includes erosive and non-erosive counterparts. The evaluation of intra-esophageal damage is of paramount importance because patients with erosive and those with non-erosive GERD have distinct manifestations and prognoses. Although proton-pump inhibitor (PPI) is the treatment of choice for erosive patients with excellent therapeutic response, the majority of reflux patients can be classified with non-erosive reflux disease (NERD).Narrow-band imaging (NBI) is a novel, noninvasive optical technique that adjusts reflected light to improve the contrast of capillary patterns compared with conventional illumination. Based on the standard procedure of sequential conventional white-light, NBI, and magnified NBI, the investigators have validated the reliability of the diagnostic testing. The investigators will also enroll NERD patients to test their therapeutic response to rabeprazole. The investigators can find out the best strategy to identify the PPI responder.
Gastroesophageal reflux disease (GERD) is a common disorder in Asia that includes erosive
and non-erosive counterparts. The evaluation of intra-esophageal damage is of paramount
importance because patients with erosive and those with non-erosive GERD have distinct
manifestations and prognoses. Although proton-pump inhibitor (PPI) is the treatment of
choice for erosive patients with excellent therapeutic response, the majority of reflux
patients can be classified with non-erosive reflux disease (NERD).1 Not all of them
demonstrate a favorable response to PPI treatment because the pathogenesis of NERD is in
part associated with psychosomatic pathways.2 Their therapeutic response to PPI is
unpredictable. Therefore, how to improve the diagnosis of reflux-induced mucosal damage
under endoscopy is a worthwhile endeavor.
Minimal change esophagitis is commonly accepted as part of the spectrum of reflux
esophagitis in Japan.3,4 This category is defined as "erythema without sharp demarcation,
whitish turbidity, and/or invisibility of vessels due to these findings".3 Although the
minimal change disease (MCD) can be recognized in a significant number of patients with
reflux using endoscopy-first policy, the major drawback of this category from the Los
Angeles system is due to a poor interobserver agreement (κ statistic = 0.2).
Narrow-band imaging (NBI) is a novel, noninvasive optical technique that adjusts reflected
light to improve the contrast of capillary patterns compared with conventional
illumination.5 This system is highly applicable in the detection of early-stage mucosal
lesions, including oral cancer, Barrett's esophagus, gastric cancer, and colonic
neoplasm.6-10 For the reflux patients we face on a daily basis, the NBI system has been
proven to improve the intraobserver and interobserver reproducibilities in grading
esophagitis with small erosive foci (improving overall κ value to 0.62 versus 0.45).11
Corresponding to the crowding of capillaries, inflamed mucosal breaks appear dark brown on
NBI, which produces intense contrast against the normal squamous epithelium and the stomach
mucosa. These properties may improve our ability to delineate the margins of small
inflammatory foci. Based on this advantage, we plausibly hypothesize the use of this system
may improve the description of MCD and enable the prediction of therapeutic response to PPI.
Testing this hypothesis is the main goal of our study.
Aim of the Study To assess the clinical utility and therapeutic implications of NBI in
evaluating reflux patients with minimal mucosal damage.
;
Observational Model: Case-Only, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02135107 -
A Double-blind Comparative Study of the Efficacy and Safety of E3810 10mg Once and Twice Daily in Maintenance Therapy for PPI Resistant Gastroesophageal Reflux Disease Patients
|
Phase 3 | |
Completed |
NCT01432392 -
Symptom Control and Impact on Daily Life in Patients With Gastroesophageal Reflux Disease
|
N/A | |
Recruiting |
NCT01249482 -
Symptom Assessment for GERD Patients Receiving H. Pylori Eradication
|
N/A | |
Completed |
NCT01578642 -
Feasibility Study for Evaluating the Effect of Electrical Stimulation on Lower Esophageal Sphincter Pressure and Esophageal Acid Exposure in Patients With Gastroesophageal Reflux Disease
|
Phase 2 | |
Completed |
NCT01200550 -
The Study to Describe Symptom Control and Impact on Daily Life in Gastroesophageal Reflux Disease (GERD) Patients
|
N/A | |
Completed |
NCT00998244 -
Study to Evaluate the Effect of a Very Low Carbohydrate Diet on Gastroesophageal Reflux Disease
|
N/A | |
Completed |
NCT00978016 -
A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD)
|
Phase 2 | |
Unknown status |
NCT01128608 -
The Effect of High PCO2 Solution on Esophageal Acid Sensation
|
N/A | |
Completed |
NCT00768196 -
Prevalence of EED and Quality of Life Evaluated by Gastroesophageal Reflux Disease (GERD)-Q in Korean GERD Patients
|
N/A | |
Completed |
NCT00768443 -
Symptoms and Management Strategies in Gastroesophageal Reflux Disease (GERD)
|
N/A | |
Recruiting |
NCT00498082 -
Determinants of Efficacy of EsophyX Treatment in Gastro-Esophageal Reflux Disease
|
N/A | |
Completed |
NCT00378898 -
Feasibility of Placing Bravo PH Capsule in Proximal Esophagus
|
N/A | |
Completed |
NCT00507377 -
Foreshortened Esophagus and Its Surgical Therapy
|
||
Completed |
NCT00217347 -
Evaluation of Efficiency of Esophageal Capsule Endoscopy in the Screening of Patients With Gastroesophageal Reflux Disease or Dyspepsia as Compared to Upper Endoscopy
|
N/A | |
Completed |
NCT00165022 -
Development of a Novel Disease-Specific Quality of Life Questionnaire for Gastroesophageal Reflux Disease (GERD) Patients in Chinese Population
|
N/A | |
Completed |
NCT00625495 -
Study Comparing the Effects of Esomeprazole Adminstered Orally and Intravenously on Basal and Pentrigastrin-stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD)
|
Phase 4 | |
Completed |
NCT00214552 -
Evaluate the Effects on Asthma Control of Rabeprazole Given Twice Daily in Subjects With Asthma.
|
Phase 3 | |
Completed |
NCT00618150 -
Patient Education in Gastroesophageal Reflux Disease
|
N/A | |
Completed |
NCT03299985 -
Diaphragmatic Myofascial Release in Gastroesophageal Reflux Disease
|
N/A | |
Completed |
NCT03284177 -
A Trial of C13-CAC Breath Test in PPI Resistant GERD Patients
|
Phase 2 |